GLOBAL LAG3 PURE PLAY, page-9

"anecdotal evidence is not admissible… "

Yes and no. This was a Phase I trial for "... evaluating the safety, tolerability and recommended Phase II dose ...". Yes, they cannot report "statistically significant" data/info results if for example in one or two cases they have seen remission. But it is an indication and encouraging results going into Phase II. ... put it this way, even one remission (while not study, as phase I, not intended to consider), is a better results than these patients dying ... well, to say the least.

For the benefit of others, something we need to keep in mind is that IMM is taking on the real challenging end of the cancer where other drugs are not working, and that simply translates to patients otherwise dying. A lot of people may for example look at the summary table I posted and think, "What is the fuss about?" ... Let me tell you, it is a BIG deal, in fact HUGE.